 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 06, 2021 GLOBE NEWSWIRE -- F-star Therapeutics, Inc. Nasdaq: FSTX the Company or F-star, a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has commenced an underwritten public offering of its common stock. F-star also intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the aggregate number of shares of common stock offered in the public offering on the same terms and conditions. All of the shares of common stock in the offering are to be sold by F-star. 